Exploring novel combinations of PI3K/AKT/mTOR inhibitors may offer a new perspective on breast cancer management, particularly for cases exhibiting resistance to endocrine therapy and a higher risk of recurrence. Here, PIK3CA is linked to breast carcinoma.